Search company, investor...

TriReme Medical


Series E | Alive

Total Raised


Last Raised

$18M | 10 yrs ago

About TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

Headquarters Location

7060 Koll Center Pkwy Suite 300

Pleasanton, California, 94566,

United States


Missing: TriReme Medical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TriReme Medical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing TriReme Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TriReme Medical is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

TriReme Medical Patents

TriReme Medical has filed 1 patent.

The 3 most popular patent topics include:

  • Cardiac procedures
  • Interventional cardiology
  • Vascular diseases
patents chart

Application Date

Grant Date


Related Topics




Vascular diseases, Vascular procedures, Interventional radiology, Implants (medicine), Vascular surgery


Application Date


Grant Date



Related Topics

Vascular diseases, Vascular procedures, Interventional radiology, Implants (medicine), Vascular surgery



Latest TriReme Medical News

Chocolate Touch Catheter to Treat PAD Receives FDA Approval

Nov 18, 2022

Genesis MedTech Group announces that the Food and Drug Administration (FDA) has approved the Chocolate Touch Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery. The drug-coated balloon (DCB) was shown to have statistically superior patency and non-inferior safety at 12 months as compared with Lutonix DCB based on a head-to-head, randomized trial of patients with symptomatic femoropopliteal disease. [1] The Chocolate Touch showed statistically superiority in its primary efficacy endpoint of 12-month True DCB Success– a measure of the target vessel remaining patent without the need for bail-out stenting. Primary patency was 78.8% for Chocolate Touch and 67.7% for Lutonix DCB at 12mo (psuperiority=0.0386); by Kaplan-Meier (KM) estimate it was 83.3% for the Chocolate Touch and 73.0% for Lutonix DCB at 12 months[1] The primary safety endpoint of 12-month freedom from major adverse events (MAE) was 88.9% for those treated with the Chocolate Touch versus 84.6% for Lutonix DCB (Pnon-inferiority <0.0001. [1] Chocolate Touch results reported the lowest all-cause KM mortality value as compared to reported mortality for FDA approved DCBs in pivotal studies. Mortality rates for Chocolate Touch using KM estimates at 3 years were 6.7% for the Chocolate Touch and 11.1% for the Lutonix DCB. “I am very excited to see the Chocolate Touch, a next-generation drug coated balloon, is now available for patients across the United States. This technology is an important tool in the armamentarium for the treatment of patients with peripheral artery disease,” stated Mehdi H. Shishehbor, DO, MPH, PhD, University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH, the Chocolate Touch trial’s Co-Principal Investigator. The Chocolate Touch drug-coated balloon is the world’s first and only balloon catheter that integrates therapeutic agent delivery with the next generation angioplasty platform, for the treatment of peripheral arterial disease. It is designed to open in small sections using pillow-like structures coated with a therapeutic agent. With the goal of providing patients suffering from peripheral arterial disease with an alternative treatment to traditional drug-coated balloon angioplasty. “This next generation paclitaxel DCB is based on the Chocolate mechanism of pillow-and-groove formation resulting in an increased balloon surface facilitating effective drug release to the vessel wall and potentially reducing the need for permanent implants. The recently completed randomized, controlled study demonstrated excellent primary results, with statistical superior effectiveness as compared to the control drug coated balloon. The Chocolate Touch is a drug coated balloon category of its own,” commented co-principal Investigator Professor Thomas Zeller, Universitaets-Herzzentrum, Bad Krozingen, Germany. Warren Wang, Chairman and CEO of Genesis MedTech Group said, “The Chocolate Touch FDA approval provides U.S. physicians and their patients a next-generation drug-coated balloon with exceptional safety and efficacy to use in treating patients with PAD. This approval demonstrate our commitment to bring innovation solutions to enhance the standard of care of millions of patients suffering from peripheral vascular diseases.” The company is planning to launch this product in the US through its subsidiary, G Vascular. References MH Shishehbor, T Zeller, M Werner, M Brodmann, H Parise, A Holden, M Lichtenberg, SA Parikh, VS Kashyap, C Pietras, D Tirziu, S Ardakani, U Beschorner, P Krishnan, KA Niazi, AU Wali,  AJ Lansky. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation. 2022; 145: 1645–1654

TriReme Medical Frequently Asked Questions (FAQ)

  • Where is TriReme Medical's headquarters?

    TriReme Medical's headquarters is located at 7060 Koll Center Pkwy, Pleasanton.

  • What is TriReme Medical's latest funding round?

    TriReme Medical's latest funding round is Series E.

  • How much did TriReme Medical raise?

    TriReme Medical raised a total of $52.52M.

  • Who are the investors of TriReme Medical?

    Investors of TriReme Medical include Three Arch Partners, Adams Street Partners, EDBI and Luminor Capital.

  • Who are TriReme Medical's competitors?

    Competitors of TriReme Medical include ArraVasc, Tryton Medical, Micell Technologies, Amaranth Medical, IDev Technologies and 12 more.

Compare TriReme Medical to Competitors

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Svelte Medical Systems

Svelte Medical Systems is engaged in the development of highly deliverable balloon expandable stents. The Svelte IDS is designed to realize the clinical, time and cost-savings benefits of direct stenting in a single platform. Svelte is developing a Sirolimus eluting stent that has non-inflammatory properties, potentially making it less irritating to the vessel lining than stents with typical polymeric coatings. The Svelte DES is being developed to have the same drug release kinetics as the market leaders while potentially minimizing inflammation in the vessel to reduce the need for long term dual anti-platelet therapy.


SquareOne is developing a stent delivery system.

Micell Technologies

Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

Tryton Medical Logo
Tryton Medical

Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

Intella Interventional Systems

Stent systems develops angioplasty catheters and guidewires, and related interventional products

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.